.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Harvard Business School
Cipla
AstraZeneca
Julphar
Mallinckrodt
McKesson
Federal Trade Commission
Merck
UBS

Generated: September 25, 2017

DrugPatentWatch Database Preview

ZOLOFT Drug Profile

« Back to Dashboard

What is the patent landscape for Zoloft, and when can generic versions of Zoloft launch?

Zoloft is a drug marketed by Pfizer and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-nine patent family members in forty-five countries.

The generic ingredient in ZOLOFT is sertraline hydrochloride. There are twenty-two drug master file entries for this compound. Sixty suppliers are listed for this compound. Additional details are available on the sertraline hydrochloride profile page.

Summary for Tradename: ZOLOFT

Patents:2
Applicants:1
NDAs:2
Suppliers / Packagers: see list13
Bulk Api Vendors: see list47
Clinical Trials: see list124
Patent Applications: see list2,580
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZOLOFT at DailyMed

Pharmacology for Tradename: ZOLOFT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
ZOLOFT
sertraline hydrochloride
TABLET;ORAL019839-005Mar 6, 1996ABRXYesNo► Subscribe► Subscribe► Subscribe
Pfizer
ZOLOFT
sertraline hydrochloride
CONCENTRATE;ORAL020990-001Dec 7, 1999AARXYesYes► Subscribe► SubscribeY► Subscribe
Pfizer
ZOLOFT
sertraline hydrochloride
TABLET;ORAL019839-003Dec 30, 1991DISCNYesNo► Subscribe► Subscribe► Subscribe
Pfizer
ZOLOFT
sertraline hydrochloride
TABLET;ORAL019839-001Dec 30, 1991ABRXYesNo► Subscribe► Subscribe► Subscribe
Pfizer
ZOLOFT
sertraline hydrochloride
TABLET;ORAL019839-002Dec 30, 1991ABRXYesYes► Subscribe► Subscribe► Subscribe
Pfizer
ZOLOFT
sertraline hydrochloride
CONCENTRATE;ORAL020990-001Dec 7, 1999AARXYesYes► Subscribe► SubscribeY► Subscribe
Pfizer
ZOLOFT
sertraline hydrochloride
TABLET;ORAL019839-004Dec 30, 1991DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZOLOFT

Paragraph IV (Patent) Challenges for ZOLOFT

Drugname Dosage Strength RLD Submissiondate
sertraline hydrochlorideTablets150 mg and 200 mgZoloft11/9/2005

International Patent Family for Tradename: ZOLOFT

Country Document Number Estimated Expiration
Spain2209490► Subscribe
Ukraine72743► Subscribe
South Korea100417200► Subscribe
Australia766202► Subscribe
Hungary0104470► Subscribe
Gulf Cooperation Council0000175► Subscribe
Peru11082000► Subscribe
New Zealand510756► Subscribe
CroatiaP20010263► Subscribe
Hong Kong1040199► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Moodys
McKinsey
Chinese Patent Office
Merck
Covington
Cipla
Cerilliant
Teva
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot